Skip to main content

Milestone 9.B

Accelerate the development of the next generation CNS imaging ligands and biofluid molecular signatures targeting a variety of disease processes (neuroinflammation, bioenergetic/metabolic compromise, oxidative stress, synaptic pathology) that can be used as research tools or developed into diagnostic, prognostic, theragnostic or target engagement biomarkers.


Success Criteria

  • Initiate synthesis and testing of CNS imaging ligands (PET/SPECT) for at least 12 novel, prioritized candidate targets.  Ensure that these reagents are made available as open source tools for target validation and predictive drug development.

  • Identify at least 6 multi-omic biomarker signatures (metabolomic, proteomic, cell-free RNAseq etc.) that can be quantitatively measured in peripheral fluids and have been validated across at least 3 diverse cohorts.


Research Implementation Area
Biomarkers
Timeline
2014–2024
Status
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations